PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16018639

Idesolide: a new spiro compound from Idesia polycarpa.

Seung Hyun Kim·Sang Hyun Sung·Soo Young Choi·Young Keun Chung·Jinwoong Kim·Young Choong Kim
View original source ↗Export metadata ↓

Abstract

[structure: see text]. Idesolide, a new spiro compound possessing tetrahydrobenzodioxole structure, was isolated from the fruits of Idesia polycarpa Maxim. Its structure was established by NMR and MS spectroscopic analysis with single-crystal X-ray experiments. Idesolide significantly reduced nitric oxide production induced by lipopolysaccharide in BV2 microglial cells.

Explore related subjects

Anti-Inflammatory AgentsCrystallography, X-RayFruitLipopolysaccharidesMass SpectrometryMolecular ConformationMolecular StructureNitric OxideNuclear Magnetic Resonance, BiomolecularSalicaceaeSpiro CompoundsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Seung Hyun Kim, Sang Hyun Sung, Soo Young Choi, Young Keun Chung, Jinwoong Kim, Young Choong Kim. 2005-07-21. Idesolide: a new spiro compound from Idesia polycarpa.. https://doi.org/10.1021/ol051105f

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

A randomized comparison of dexamethasone 0.15 mg/kg versus 0.6 mg/kg for the treatment of moderate to severe croup.

BACKGROUND: Although previous studies have shown that dexamethasone is useful in croup, the optimal dosage has not been clarified yet. The aim of this study was to investigate the effectiveness of dexamethasone 0.15 mg/kg single dose compared with the recommended dose of 0.6 mg/kg for treatment of hospitalized children with moderate to severe croup. METHOD: Forty-one children aged 6 months to 5 years admitted from March 2001 to October 2003 at the pediatric ward of Hatyai Hospital with moderate to severe croup were recruited for the study. After random allocation, each child received a single intravenous injection of either dexamethasone 0.6 mg/kg (maximum dose 12 mg) or 0.15 mg/kg (maximum dose 3 mg). All children were given a single dose of epinephrine nebulization at the beginning of the study. The croup scores were measured at 0, 1, 2, 3, 4, 6, 8, 10 and 12 h after the dexamethasone injection. RESULTS: One hour following the injection, the mean croup scores were significantly reduced from baseline values in both groups (p<0.01). There was no difference in the mean croup scores between the two groups at any time. Median times to croup scores equal or less than two in both high- and low-dose groups were 8 and 7.9 h, respectively. No patient required intubation or was removed from the study because of a rising croup score after enrollment. There was no significant adverse reaction from dexamethasone treatment in either group. CONCLUSION: Dexamethasone 0.15 and 0.6 mg/kg are equally effective in the treatment of moderate to severe croup.

Anti-Inflammatory Agents↗